Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press
Series of Journals
Center for Evidence-Based and Translational Medicine of Wuhan University
The title
The title
The keywords
The author
Submit
Home
About us
Journal Introduction
Chief Editor
Editorial Committee
Author Center
Submission Guide
Assignment Agreement
Articles
Subscribe
Copyright
Contact us
Draft submission system
Author login
Author register
Reviewer login
Editor login
Home
Results
The title
The title
The keywords
The author
A total of
7
result was found. Results that relate to
Pembrolizumab
帕博利珠单抗治疗后应用阿莫西林致斑丘疹 1 例
Jing GONG
Xiao-Lin CHEN
Xue-Li LIU
Jun YANG
DOI:10.19960/j.issn.1005-0698.202301013
Pembrolizumab
Amoxicillin
Maculopapular drug eruption
Immune activation
Details
Download
Mobile
1 例帕博利珠单抗致甲状腺功能减退的病例分析
Fei-Long TAN
Hong-Ying XIA
Zhong-Juan WANG
Li DING
Li-Na YOU
Li ZHOU
Jian JIN
DOI:10.19960/j.issn.1005-0698.202302014
Pembrolizumab
Immune checkpoint inhibitors
Hypothyroidism
Adverse drug reaction
Details
Download
Mobile
帕博利珠单抗致重度免疫相关性溃疡性结肠炎1例
Jin-Jin ZOU
Ji-Liang ZHANG
Ni LI
Ding-Yi LIU
DOI:10.19960/j.issn.1005-0698.202311015
Pembrolizumab
Lung squamous cell carcinoma
Severe immune-related ulcerative colitis
Adverse drug reactions
Details
Download
Mobile
帕博利珠单抗致严重免疫性肝损伤再挑战1例分析
LIU Min
YANG Limei
YIN Yue
ZHAO Bingqing
DOI:10.12173/j.issn.1005-0698.202311017
Pembrolizumab
Immune related liver injury
Rechallenge of immunotherapy
Details
Download
Mobile
帕博利珠单抗联合化疗治疗晚期恶性胸膜间皮瘤的成本-效用分析
HU Yunjia
ZOU Keqing
HOU Yanhong
DOI:10.12173/j.issn.1005-0698.202407011
Pembrolizumab
Chemotherapy
Advanced malignant pleural mesothelioma
Partitioned survival model
Cost-utility analysis
Pharmacoeconomic evaluation
Details
Download
Mobile
帕博利珠单抗注射液致过敏性休克1例
HUANG Shuzhen
CHEN Xiongjian
DOI:10.12173/j.issn.1005-0698.202408052
Pembrolizumab
Anaphylaxis
Adverse drug reaction
Details
Download
Mobile
帕博利珠单抗致中毒性表皮坏死松解症1例
HUANG Lingling
LI Xialin
HUANG Guangyao
LUO Peng
WANG Weimin
WANG Junping
DOI:10.12173/j.issn.1005-0698.202408019
Pembrolizumab
Lung cancer
Toxic epidermal necrolysis
Adverse drug reaction
Details
Download
Mobile